Full-Time

Senior Scientist

Molecular Bioanalytics

Posted on 8/13/2024

Editas Medicine

Editas Medicine

201-500 employees

Develops gene editing treatments using CRISPR

Biotechnology

Mid, Senior

Cambridge, MA, USA

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD in pharmaceutics, medicinal chemistry, analytical chemistry, DMPK or a relevant discipline, with a minimum of 3 years of drug discovery experience; Bachelor’s/Master’s degrees with extensive and relevant industry experience will also be considered.
  • Extensive knowledge and experience in conducting quantitative bioanalysis using molecular bioanalytical techniques such as qPCR, ddPCR to support discovery and development projects.
  • Demonstrated knowledge and experience in establishing bioanalytical methods, ADME, PK/PD for a variety of therapeutic modalities, ideally in preclinical environment.
  • Experience in leading and developing strong, technical, delivery-focused teams is a plus.
  • Experience with gene editing or gene delivery technologies and lipid nanoparticle delivery is highly desired.
  • Excellent communication skills and proven ability to collaborate with interdisciplinary teams, along with exceptional scientific thinking and problem-solving skills.
  • Ability to multi-task to meet research and development goals in a fast-paced environment.
Responsibilities
  • Establishing and executing on routine workflows for method development using techniques such as molecular bioanalytical assays (qPCR, ddPCR) to support quantitative bioanalysis and apply innovative solutions to solve complex problems to advance the pipeline.
  • Develop and execute PCR-based methods, sample analysis, data generation, and report writing for preclinical and clinical samples.
  • Develop nucleic acid extraction (DNA/RNA) and quantification from a broad-spectrum animal tissues.
  • Responsible for the design and execution of in vitro and in vivo studies to address ADME questions aligned with our overall scientific strategy.
  • Execute bioanalytical assay development strategies to characterize ADME, PK and biodistribution properties of the drug product and address key scientific questions.
  • Ensure that the data obtained is of the highest quality, and stage appropriate.
  • Write bioanalytical assay protocols and reports that are suitable for inclusion in registration dossiers.
  • Contribute effectively to patents, reports, and publications of scientific findings.
  • Model behaviors of a strong leader and mentor to staff members as appropriate.
  • Establish strong partnerships across sites and across functions; Work cross-functionally within the R&D organization.
  • Ensure compliance with electronic notebooks (ELN), high data integrity and company policies.

Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and selling them. Editas Medicine aims to create effective and lasting therapies that can enhance the quality of life for patients suffering from serious health conditions. Unlike many competitors, Editas has a strong emphasis on developing a wide range of experimental medicines and actively shares clinical data with the public. Their goal is to provide transformative treatments for patients worldwide, while also exploring partnerships to expand their reach and capabilities.

Company Stage

IPO

Total Funding

$321M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

3%

1 year growth

0%

2 year growth

-3%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Genevant Sciences could enhance targeted delivery systems for gene therapies.
  • $50 million financing with DRI Healthcare Trust supports pipeline advancement and in-vivo programs.
  • Promising EDIT-101 trial results highlight potential to address genetic blindness.

What critics are saying

  • 65% workforce reduction may lead to operational challenges and development delays.
  • Pivot to in-vivo gene editing increases dependency on new research direction's success.
  • Reliance on external partnerships like Genevant Sciences may pose collaboration risks.

What makes Editas Medicine unique

  • Editas Medicine leverages CRISPR technology for precise gene editing therapeutics.
  • The company focuses on in-vivo gene editing, targeting stem cells and the liver.
  • Editas has substantial patent filings and access to foundational genome editing technologies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Tuition Reimbursement

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Plan

Wellness Program

Unlimited Paid Time Off

INACTIVE